Incorporating human dosimetry and exposure into high-throughput in vitro toxicity screening

Toxicological Sciences

Volumn 117, Issue 2, 2010, Pages 348-358

  Rotroff, Daniel M ^a,b   Wetmore, Barbara A ^c   Dix, David J ^a   Ferguson, Stephen S ^d   Clewell, Harvey J ^c   Houck, Keith A ^a   LeCluyse, Edward L ^d   Andersen, Melvin E ^c   Judson, Richard S ^a   Smith, Cornelia M ^d   Sochaski, Mark A ^c   Kavlock, Robert J ^a   Boellmann, Frank ^c   Martin, Matthew T ^a   Reif, David M ^a   Wambaugh, John F ^a   Thomas, Russell S ^c  

^a U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^b University of North Carolina at Chapel Hill   (United States)

^c HAMNER INSTITUTES FOR HEALTH SCIENCES   (United States)

^d Invitrogen Corporation/CellzDirect   (United States)

Author keywords

High throughput screening; Human exposure; Reverse dosimetry; ToxCast

Indexed keywords

PYRITHIOBAC SODIUM; TOXIC SUBSTANCE; TRICLOSAN; UNCLASSIFIED DRUG;

ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOSIMETRY; DRUG ACTIVITY; DRUG EXPOSURE; HIGH THROUGHPUT SCREENING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; METABOLIC CLEARANCE RATE; PLASMA PROTEIN BINDING; TOXICITY;

CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HEPATOCYTES; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MALE; METABOLIC CLEARANCE RATE; PROTEIN BINDING; RISK ASSESSMENT; TOXICITY TESTS; XENOBIOTICS;

EID: 77956906710     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfq220     Document Type: Article

References (48)

1. Abbott, A. (2009). Toxicity testing gets a makeover. Nature 461, 158.
2. Allanou, R., Hansen, B. G., and Van Der Bilt, Y. (2003). Public availability of data on EU high production volume chemicals. Part 1. Chim. Oggi. 21, 91-95.
3. Andersen, M. E., and Krewski, D. (2009). Toxicity testing in the 21st century: bringing the vision to life. Toxicol. Sci. 107, 324-330.
4. Bjorklund, H. V., and Bylund, G. (1991). Comparative pharmacokinetics and bioavailability of oxolinic acid and oxytetracycline in rainbow trout (Oncorhynchus mykiss). Xenobiotica 21, 1511-1520.
5. Blaauboer, B. J. (2003). The integration of data on physico-chemical properties, in vitro-derived toxicity data and physiologically based kinetic and dynamic as modelling a tool in hazard and risk assessment. A commentary. Toxicol. Lett. 138, 161-171.
6. Blaauboer, B. J. (2010). Biokinetic modeling and in vitro-in vivo exptrapolations. J. Toxicol. Environ. Health, Part B 13, 242-252.
7. Breithaupt, H. (2006). The costs of REACH. REACH is largely welcomed, but the requirement to test existing chemicals for adverse effects is not good news for all. EMBO Rep. 7, 968-971.
8. Brown, V. J. (2003). REACHing for chemical safety. Environ. Health Perspect. 111, A766-A769.
9. Caldwell, G. W., Yan, Z., Tang, W., Dasgupta, M., and Hasting, B. (2009). ADME optimization and toxicity assessment in early- and late-phase drug discovery. Curr. Top. Med. Chem. 9, 965-980.
10. Chhabra, R. S., Bucher, J. R., Wolfe, M., and Portier, C. (2003). Toxicity characterization of environmental chemicals by the US National Toxicology Program: an overview. Int. J. Hyg. Environ. Health 206, 437-445.
11. Cohen Hubal, E. A., Richard, A., Aylward, L., Edwards, S., Gallagher, J., Goldsmith, M. R., Isukapalli, S., Tornero-Velez, R., Weber, E., and Kavlock, R. (2010). Advancing exposure characterization for chemical evaluation and risk assessment. J. Toxicol. Environ. Health B Crit. Rev. 13, 299-313.
12. Collins, F. S., Gray, G. M., and Bucher, J. R. (2008). Toxicology. Transforming environmental health protection. Science 319, 906-907.
13. Crump, K. S. (1995). Calculation of benchmark dose from continuous data. Risk Anal. 15, 79-89.
14. De Buck, S. S., and Mackie, C. E. (2007). Physiologically based approaches towards the prediction of pharmacokinetics: in vitro-in vivo extrapolation. Expert Opin. Drug Metab. Toxicol. 3, 865-878.
15. Dix, D. J., Houck, K. A., Martin, M. T., Richard, A. M., Setzer, R. W., and Kavlock, R. J. (2007). The ToxCast program for prioritizing toxicity testing of environmental chemicals. Toxicol. Sci. 95, 5-12.
16. Foth, H., and Hayes, A. (2008). Concept of REACH and impact on evaluation of chemicals. Hum. Exp. Toxicol. 27, 5-21.
17. Gentry, P. R., Hack, C. E., Haber, L., Maier, A., and Clewell, H. J., III. (2002). An approach for the quantitative consideration of genetic polymorphism data in chemical risk assessment: examples with warfarin and parathion. Toxicol. Sci. 70, 120-139.
18. Hofer, T., Gerner, I., Gundert-Remy, U., Liebsch, M., Schulte, A., Spielmann, H., Vogel, R., and Wettig, K. (2004). Animal testing and alternative approaches for the human health risk assessment under the proposed new European chemicals regulation. Arch. Toxicol. 78, 549-564.
19. Holsapple, M. P., Afshari, C. A., and Lehman-McKeeman, L. D. (2009). Forum Series: the "Vision" for Toxicity Testing in the 21st Century: promises and conundrums. Toxicol. Sci. 107, 307-308.
20. Jamei, M., Marciniak, S., Feng, K., Barnett, A., Tucker, G., and Rostami-Hodjegan, A. (2009). The Simcyp((R)) Population-based ADME Simulator. Expert Opin. Drug Metab. Toxicol. 5, 211-223.
21. Jones, H. M., and Houston, J. B. (2004). Substrate depletion approach for determining in vitro metabolic clearance: time dependencies in hepatocyte and microsomal incubations. Drug Metab. Dispos. 32, 973-982.
22. Judson, R., Richard, A., Dix, D. J., Houck, K., Martin, M., Kavlock, R., Dellarco, V., Henry, T., Holderman, T., Sayre, P., et al. (2009). The toxicity data landscape for environmental chemicals. Environ. Health Perspect. 117, 685-695.
23. Judson, R. S., Houck, K. A., Kavlock, R. J., Knudsen, T. B., Martin, M. T., Mortensen, H. M., Reif, D. M., Rotroff, D. M., Shah, I., Richard, A. M., et al. (2010). In vitro screening of environmental chemicals for targeted testing prioritization: the ToxCast project. Environ. Health Perspect. 118, 485-492.
24. Kavlock, R. J., Austin, C. P., and Tice, R. R. (2009). Toxicity testing in the 21st century: implications for human health risk assessment. Risk Anal. 29, 485-487; discussion 492-497.
25. Knight, A. (2008). Non-animal methodologies within biomedical research and toxicity testing. ALTEX 25, 213-231.
26. Kohli, J. D., Khanna, R. N., Gupta, B. N., Dhar, M. M., Tandon, J. S., and Sircar, K. P. (1974). Absorption and excretion of 2,4-dichlorophenoxyacetic acid in man. Xenobiotica 4, 97-100.
27. Krewski, D., Andersen, M. E., Mantus, E., and Zeise, L. (2009). Toxicity testing in the 21st century: implications for human health risk assessment. Risk Anal. 29, 474-479.
28. Li, A. P., Lu, C., Brent, J. A., Pham, C., Fackett, A., Ruegg, C. E., and Silber, P. M. (1999). Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential. Chem. Biol. Interact. 121, 17-35.
29. Locke, P. A., and Myers, D. B. (2010). Implementing the National Academy's vision and strategy for toxicity testing: opportunities and challenges under the U.S. Toxic Substances Control Act. J. Toxicol. Environ. Health, Part B 13, 376-384.
30. Martin, M. T., Judson, R. S., Reif, D. M., Kavlock, R. J., and Dix, D. J. (2009). Profiling chemicals based on chronic toxicity results from the U.S. EPA ToxRef Database. Environ. Health Perspect. 117, 392-399.
31. Naritomi, Y., Terashita, S., Kimura, S., Suzuki, A., Kagayama, A., and Sugiyama, Y. (2001). Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab. Dispos. 29, 1316-1324.
32. Nielsen, P., and Gyrd-Hansen, N. (1996). Bioavailability of oxytetracycline, tetracycline and chlortetracycline after oral administration to fed and fasted pigs. J. Vet. Pharmacol. Ther. 19, 305-311.
33. National Research Council (NRC). (1983). Risk Assessment in the Federal Government: Managing the Process. National Academy of Sciences Press, Washington, DC.
34. National Research Council (NRC). (2007). Toxicity Testing in the 21st Century: A Vision and a Strategy. National Research Council of the National Academies, Washington, DC.
35. National Toxicology Program (NTP). (2008). NTP-CERHR Monograph on the Potential Human Reproductive and Developmental Effects of Bisphenol A. National Institutes of Environmental Health Sciences, Research Triangle Park, NC. NIH Publication No. 08-5994.
36. Obach, R. S. (1999). Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab. Dispos. 27, 1350-1359.
37. Payne, M. P., and Kenny, L. C. (2002). Comparison of models for the estimation of biological partition coefficients. J. Toxicol. Environ. Health A 65, 897-931.
38. Poulin, P., and Theil, F. P. (2002). Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J. Pharm. Sci. 91, 129-156.
39. Rostami-Hodjegan, A., and Tucker, G. T. (2007). Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat. Rev. Drug Discov. 6, 140-148.
40. Rowland, M., Benet, L. Z., and Graham, G. G. (1973). Clearance concepts in pharmacokinetics. J. Pharmacokinet. Biopharm. 1, 123-136.
41. Rule, A. D., Gussak, H. M., Pond, G. R., Bergstralh, E. J., Stegall, M. D., Cosio, F. G., and Larson, T. S. (2004). Measured and estimated GFR in healthy potential kidney donors. Am. J. Kidney Dis. 43, 112-119.
42. Sauerhoff, M. W., Braun, W. H., Blau, G. E., and Gehring, P. J. (1977). The fate of 2,4-dichlorophenoxyacetic acid (2,4-D) following oral administration to man. Toxicology 8, 3-11.
43. Shiran, M. R.,Proctor, N. J.,Howgate, E. M., Rowland-Yeo, K.,Tucker, G. T.,and Rostami-Hodjegan, A. (2006). Prediction of metabolic drug clearance in humans: in vitro-in vivo extrapolation vs allometric scaling. Xenobiotica 36, 567-580.
44. U.S. Environmental Protection Agency (EPA). (1998). Chemical Hazard Data Availability Study: What Do We Really Know about the Safety of High Production Volume Chemicals. U.S. Environmental Protection Agency, Office of Pollution Prevention and Toxics, Washington, DC.
45. Verwei, M., van Burgsteden, J. A., Krul, C. A., van de Sandt, J. J., and Freidig, A. P. (2006). Prediction of in vivo embryotoxic effect levels with a combination of in vitro studies and PBPK modelling. Toxicol. Lett. 165, 79-87.
46. Volkel, W., Colnot, T., Csanady, G. A., Filser, J. G., and Dekant, W. (2002). Metabolism and kinetics of bisphenol a in humans at low doses following oral administration. Chem. Res. Toxicol. 15, 1281-1287.
47. Waters, N. J., Jones, R., Williams, G., and Sohal, B. (2008). Validation of a rapid equilibrium dialysis approach for the measurement of plasma protein binding. J. Pharm. Sci. 97, 4586-4595.
48. Wilson, M. P., and Schwarzman, M. R. (2009). Toward a new U.S. chemicals policy: rebuilding the foundation to advance new science, green chemistry, and environmental health. Environ. Health Perspect. 117, 1202-1209.